India's weight-loss drug market explodes with generic competition.

India's weight-loss drug market explodes with generic competition. Following semaglutide's patent expiration on March 20, major Indian drugmakers Dr Reddy's, Sun Pharma, and Zydus Lifesciences launched generic versions priced 50-90% below innovator Novo Nordisk's brands Ozempic and Wegovy. Novo Nordisk's monthly costs reached 8,800 to 10,850 rupees, while generics now range from 1,300 to 4,200 rupees monthly depending on format and indication. Dr Reddy's Obeda launched at 4,200 rupees monthly, Sun Pharma's Noveltreat and Sematrinity at 3,600 and 3,000 rupees respectively. This aggressive price competition marks a pivotal shift for India's emerging GLP-1 market, dramatically expanding access to weight-loss and diabetes treatments that were previously limited by high costs. The generic flood signals intense competition ahead in this fast-growing therapeutic segment.